Connect with us

News

TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer

gbafNews28

Results from a prespecified exploratory analysis of the positive ADAURA Phase III trial showed AstraZenecas TAGRISSO (osimertinib) demonstrated a clinically meaningful improvement in central nervous system (CNS) disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), after complete tumor resection.

While up to 30% of all patients with NSCLC may be diagnosed early enough to have potentially curative surgery, disease recurrence is still common in early-stage disease.1-3 CNS recurrence, when cancer spreads to the brain, is a frequent complication of EGFRm NSCLC and these patients have an especially poor prognosis.4,5

Results were presented on September 19, 2020 during the Presidential Symposium of the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (abstract #LBA1) and simultaneously published with the primary results in The New England Journal of Medicine.

This analysis showed that fewer patients treated with TAGRISSO in the adjuvant setting had recurrence events or deaths compared to placebo (11% versus 46%). Among patients whose cancer recurred, 38% of those treated with TAGRISSO had a metastatic recurrence compared to 61% of patients on placebo. TAGRISSO showed an 82% reduction in the risk of CNS recurrence or death (based on a hazard ratio [HR] of 0.18; 95% confidence interval [CI] 0.10-0.33; p<0.0001). Median CNS DFS was not yet reached in either arm.

In a post-hoc analysis, the estimated probability of observing disease recurrence in the brain at 18 months for patients treated with TAGRISSO was less than 1% versus 9% for placebo among patients who had not experienced another type of recurrence. On the primary endpoint of DFS in patients with Stage II and IIIA disease, TAGRISSO¯in the adjuvant setting reduced the risk of disease recurrence or death by 83% (HR 0.17; 95% CI 0.12-0.23; p<0.0001).

Masahiro Tsuboi, MD, PhD, director of the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East in Japan, and a principal investigator in the ADAURA Phase III trial, said: Its time to change the notion that treatment for early-stage EGFR-mutated lung cancer ends after surgery, since recurrence rates are still very high even after adjuvant chemotherapy. These new data showing low rates of recurrence, particularly in the brain, combined with the remarkable disease-free survival benefit, clearly demonstrate that TAGRISSO provides patients with more time living cancer-free.

Jos Baselga, Executive Vice President, Oncology R&D, said: Once lung cancer has spread to the brain, outcomes are typically devastating for patients. We are now seeing TAGRISSO expanding on its proven efficacy in treating progression in the brain in the metastatic setting as a result of its ability to cross the blood-brain barrier. The striking new data show that TAGRISSO prevents the development of brain metastases in patients with early disease and reinforce that this medicine is truly transformative for patients with EGFR-mutated lung cancer. TAGRISSO should become the standard of care in the adjuvant setting, just as it is for patients with metastatic disease around the world.

Summary of exploratory results on CNS recurrence in the ADAURA Phase III trial

 

TAGRISSO n=339

Placebo n=343

CNS DFS

 

HR (95% CI)

0.18 (0.10-0.33);

p-value

p<0.0001

CNS DFS events, patients (%):

6 (2%)

39 (11%)

CNS recurrence

4 (1%)

33 (10%)

Deathi

2 (1%)

6 (2%)

DFS events, patients (%):

37 (11%)

159 (46%)

Type of disease recurrence

n=37

n=157

Local/regional only

23 (62%)

61 (39%)

Distant

14 (38%)

96 (61%)

Deathii

0

2 (1%)

i. Death in absence of CNS disease recurrence, or death within two visits of baseline where the patient has no evaluable assessments or no baseline data. ii. Death in the absence of disease recurrence (any site), or death within two visits of baseline where the patient has no evaluable assessments or no baseline data.

The safety and tolerability of TAGRISSO in this trial was consistent with previous trials in the metastatic EGFRm NSCLC setting. Adverse events at Grade 3 or higher from all causes occurred in 10% of patients in the TAGRISSO arm versus 3% in the placebo arm as assessed by investigators.

TAGRISSO is not currently approved in the adjuvant setting in any country. TAGRISSO received Breakthrough Therapy Designation in July 2020 for the adjuvant treatment of patients with early-stage EGFRm NSCLC after complete tumor resection with curative intent. TAGRISSO is approved for the 1st-line treatment of patients with metastatic EGFRm NSCLC and for the treatment of metastatic EGFR T790M mutation-positive NSCLC in the US, Japan, China, the EU and many other countries around the world.

TAGRISSO IMPORTANT SAFETY INFORMATION

  • There are no contraindications for TAGRISSO
  • Interstitial lung disease (ILD)/pneumonitis occurred in 3.9% of the 1142 TAGRISSO-treated patients; 0.4% of cases were fatal. Withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (eg, dyspnea, cough and fever). Permanently discontinue TAGRISSO if ILD is confirmed
  • Heart rate-corrected QT (QTc) interval prolongation occurred in TAGRISSO-treated patients. Of the 1142 TAGRISSO-treated patients in clinical trials, 0.9% were found to have a QTc >500 msec, and 3.6% of patients had an increase from baseline QTc >60 msec. No QTc-related arrhythmias were reported. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia
  • Cardiomyopathy occurred in 2.6% of the 1142 TAGRISSO-treated patients; 0.1% of cardiomyopathy cases were fatal. A decline in left ventricular ejection fraction (LVEF) ‰¥10% from baseline and to <50% LVEF occurred in 3.9% of 908 patients who had baseline and at least one follow-up LVEF assessment. Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors. Assess LVEF in patients who develop relevant cardiac signs or symptoms during treatment. For symptomatic congestive heart failure, permanently discontinue TAGRISSO
  • Keratitis was reported in 0.7% of 1142 patients treated with TAGRISSO in clinical trials. Promptly refer patients with signs and symptoms suggestive of keratitis (such as eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye) to an ophthalmologist
  • Postmarketing cases consistent with Stevens-Johnson syndrome (SJS) and erythema multiforme major (EMM) have been reported in patients receiving TAGRISSO. Withhold TAGRISSO if SJS or EMM is suspected and permanently discontinue if confirmed
  • Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the final dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the final dose
  • Most common adverse reactions (‰¥20%) were diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue and decreased appetite

INDICATIONS

  • TAGRISSO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
  • TAGRISSO is indicated for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy

Please see complete Prescribing Information, including Patient Information.

About Lung cancer

Lung cancer is the leading cause of cancer death among both men and women, accounting for about one-fifth of all cancer deaths.6 Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% classified as NSCLC.7 The majority of all NSCLC patients are diagnosed with advanced disease while approximately 25-30% present with resectable disease at diagnosis.1-3

For those with resectable tumors, the majority of patients eventually develop recurrence despite complete tumor resection and adjuvant chemotherapy.8 Early-stage lung cancer diagnoses are often only made when the cancer is found on imaging for an unrelated condition.9,10

Approximately 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia have EGFRm NSCLC.11-13 These patients are particularly sensitive to treatment with EGFR-tyrosine kinase inhibitors (TKIs) which block the cell-signaling pathways that drive the growth of tumor cells.14

About ADAURA

ADAURA is a randomized, double-blinded, global, placebo-controlled Phase III trial in the adjuvant treatment of 682 patients with Stage IB, II, IIIA EGFRm NSCLC following complete tumor resection and adjuvant chemotherapy as indicated. Patients were treated with TAGRISSO 80 mg once-daily oral tablets or placebo for three years or until disease recurrence.

The trial enrolled in more than 200 centers across more than 20 countries, including the US, in Europe, South America, Asia and the Middle East. The primary endpoint is DFS in Stage II and IIIA patients and a key secondary endpoint is DFS in Stage IB, II and IIIA patients. The data readout was originally anticipated in 2022. The trial will continue to assess OS.

About TAGRISSO

TAGRISSO (osimertinib) is a third-generation, irreversible EGFR-TKI with clinical activity against central nervous system metastases. TAGRISSO 40 mg and 80 mg once-daily oral tablets have received approval in the US, Japan, China, the EU and many countries around the world for 1st-line EGFRm advanced NSCLC and EGFR T790M mutation-positive advanced NSCLC.

AstraZeneca in lung cancer

AstraZeneca has a comprehensive portfolio of approved and potential new medicines in late-stage development for the treatment of different forms of lung cancer spanning different histologies, several stages of disease, lines of therapy and modes of action.

AstraZeneca aims to address the unmet needs of patients with EGFRm tumors as a genetic driver of disease with the approved medicines gefitinib and TAGRISSO and its ongoing Phase III trials LAURA, NeoADAURA and FLAURA2.

AstraZeneca is committed to addressing tumor mechanisms of resistance through the ongoing Phase II trials SAVANNAH and ORCHARD, which test TAGRISSO in combination with savolitinib, a selective inhibitor of c-MET receptor tyrosine kinase, along with other potential new medicines.

AstraZeneca in oncology

AstraZeneca has a deep-rooted heritage in oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With seven new medicines launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, the Company is committed to advance oncology as a key growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers.

By harnessing the power of four scientific platforms – Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing the development of personalized combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

References

1. Cagle P, et al. Lung Cancer Biomarkers: Present Status and Future Developments. Arch Pathol Lab Med. 2013;137:1191-1198. 2. Le Chevalier T. Adjuvant Chemotherapy for Resectable Non-Small-Cell Lung Cancer: Where is it Going? Ann Oncol. 2010;21:196-198. 3. Datta D, et al. Preoperative Evaluation of Patients Undergoing Lung Resection Surgery. Chest. 2003;123:2096“2103. 4. Rangachari D, et al. Brain Metastases in Patients with EGFR-Mutated or ALK-Rearranged Non-Small-Cell Lung Cancers. Lung Cancer. 2015;88:108“111. 5. Ali A, et al. Survival of Patients with Non-small-cell Lung Cancer After a Diagnosis of Brain Metastases. Curr Oncol. 2013;20(4):e300-e306. 6. World Health Organization. International Agency for Research on Cancer. Lung Fact Sheet. Available at http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed September 2020. 7. LUNGevity Foundation. Types of Lung Cancer. Available at https://www.lungevity.org/about-lung-cancer/lung-cancer-101/types-of-lung-cancer. Accessed September 2020. 8. Pignon JP et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552-3559. 9. Sethi S, et al. Incidental Nodule Management “ Should There Be a Formal Process? J Thorac Dis. 2016;8:S494-S497. 10. LUNGevity Foundation. Screening and Early Detection. Available at: https://lungevity.org/for-patients-caregivers/lung-cancer-101/screening-early-detection#1. Accessed September 2020. 11. Szumera-Ciećkiewicz A, et al. EGFR Mutation Testing on Cytological and Histological Samples in Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. Int J Clin Exp Pathol. 2013;6:2800-2812. 12. Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011;29:2121-2127. 13. Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. J Clin Pathol. 2013;66:79-89. 14. Cross DA, et al. AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer Discov. 2014;4(9):1046-1061.

Media Inquiries

Michele Meixell +1 302 885 2677

Brendan McEvoy +1 302 885 2677

News

Artprice by Artmarket.com: Condition of the Street Art market worldwide

gbafNews28

PARIS, Oct. 20, 2020 /PRNewswire/ — At its online sale on 28 May 2020, Phillips sold Banksy’s lot Happy Choppers (2003) for $39,000. That may not seem surprising until you take into account that the work was a screenprint numbered 621 from a series of 750, purchased four years earlier for $4,500… which means its value climbed 70% per year.

 

Festival Peinture Fraîche (Wet Paint Festival) at the Halle Debourg in Lyon, from 2 to 25 October, 2020 - extended until 1 November 2020
Festival Peinture Fraîche (Wet Paint Festival) at the Halle Debourg in Lyon, from 2 to 25 October, 2020 – extended until 1 November 2020

 

Festival Peinture Fraîche (Wet Paint Festival) at the Halle Debourg in Lyon, from 2 to 25 October, 2020 – extended until 1 November 2020
www.peinturefraichefestival.fr

"Street Art is a truly universal art that can be found everywhere – from Rio to Berlin – and whose place is changing very rapidly on the Art Market," observes thierry Ehrmann, President and Founder of Artmarket.com and its Artprice department. "It’s a market that took 15 years to consolidate and is at last reaching maturity. It now constitutes a segment in its own right, with its stars and its masterpieces… but also numerous editions, some more important than others… some more affordable than others."

Works ‘in circulation’

Street Art is by nature a work created in an urban environment. As soon as it leaves the street to be exhibited in a gallery or exchanged in an auction room, it necessarily loses a great deal of its essence. That said, there is quite clearly a fully fledged and dynamic Street Art market.

The development of the market for Street Art seems to have learnt a lot from a number of other relatively recent art movements (Land Art for example). Street artists can record their interventions in public spaces with photography; they can also make small works or drawings or screenprints based on original street creations, or they can create a second body of paintings and original sculptures alongside their outdoor work. All of these ‘derivatives’ are now changing hands and lots end up in auction rooms… now forming a genuinely ‘deep’ market.

The 4 pillars of the market

Jean-Michel Basquiat left his mark on the streets of New York at the start of the 1980s, but did he remain a street artist all of his (short) life? Are his paintings and his drawings – worth millions of dollars – still part of Urban Art? In 2019, works by Jean-Michel Basquiat generated $130 million on the secondary market and those by Keith Haring totalled $42 million. These two major Contemporary artists remain generally associated with Street Art… but they are not in fact catalogued as such.

A similar ambiguity seems to apply to the more recent mega-phenomenon Kaws ($108 million in 2019) who has gradually moved away from his initial practice of Street Art over the course of his career. His paintings and sculptures, offered for sale by the most powerful Contemporary art galleries, have seduced a broad international market, particularly in Asia.

Flowing somewhat ironically against this trend there is of course the anonymous artist Banksy ($28 million in 2019) who voluntarily maintains his presence in urban spaces around the world.

15 years to create a structured market…

Nobody epitomises the rapid evolution of the Street Art market more than Banksy with his auction track record:

  • His first paintings were sold at auction in 2005
  • His auction turnover peaked just before the subprime crisis
  • 10 years of more or less regular turnover growth between 2010 and 2019
  • Exceptional resilience to the coronavirus crisis

With Banksy, the Street Art movement has undoubtedly found its figurehead and in the wake of the ‘Banksy phenomenon’, a whole market has emerged with three names that have become unavoidable: the French artist Invader ($4 million in 2019), the English artist Stik ($1 million) and the American artist Obey ($1 million), the latter who, alone, sold more than 700 lots at auction in 2019.

A dozen other street artists generate several tens of thousand of dollars a year each: Jonone, Mr Brainwash, Futura 2000, Vhils, JR, etc. But the markets of the bulk of street artists are still fragile. This is true even of relatively established artists like Ernest Pignon-Ernest, whose turnover usually averages around $50,000 per year.

Specialized sessions

In February 2008, Bonhams organized the first auction sale dedicated to Street Art in London. Soon afterwards, Phillips also offered a Contemporary & Urban Art session. But the subprime crisis and its repercussions halted the development of these sessions, and they were dropped by Phillips in 2009 and by Bonhams in 2013.

Artcurial also started its Urban Art sales in 2008 … and never abandoned them. The leading French auction house, which organized four Street Art sessions in 2019, now clearly dominates this niche market. In 2009, dedicated Street Art sales generated $10 million from 3,000 lots in auctions scattered between Europe and the USA: Digard and Cornette de Saint-Cyr in Paris, Tate Ward in London, Heritage in Dallas and Julien in Los Angeles.

An exciting market

Christie’s and Sotheby’s prefer to offer Street Art works in their catalogues, especially those of their most prestigious sales. In July 2020, Sotheby’s sold Banksy’s triptych Mediterranean Sea View (2017) for $2.9 million in an extraordinary sale entitled Rembrandt to Richter. Surrounded by such respected signatures, Banksy’s work was bound to elicit strong bidding.

Indeed, the sale of any Banksy work at a physical auction will always arouse interest since his Girl with Balloon (2006) self-destructed in 2018. In February 2020 at Artcurial, Raising the steaks (2001) – a photograph taken by Steve Lazarides but framed by Banksy himself –  reached $84,500. It was not impossible that Banksy had hidden another surprise in the work, which was duly accompanied by his PEST Control (certificate of authentication issued by the artist himself). 

Contact Artprice’s Econometrics Department for your questions relating to our indices and statistics, as well as for our Personalized Study Services: [email protected]

Image: [https://imgpublic.artprice.com/img/wp/sites/11/2020/10/Festival-Peinture-Fraiche.jpg]

Copyright 1987-2020 thierry Ehrmann www.artprice.comwww.artmarket.com

Try our services (free demo): https://www.artprice.com/artist/15079/wassily-kandinsky

Subscribe to our services: https://www.artprice.com/subscription

About Artmarket:

Artmarket.com is listed on Eurolist by Euronext Paris, SRD long only and Euroclear: 7478 – Bloomberg: PRC – Reuters: ARTF.

Discover Artmarket and its Artprice department on video: https://en.artprice.com/video

Artmarket and its Artprice department was founded in 1997 by its CEO, thierry Ehrmann. Artmarket and its Artprice department is controlled by Groupe Serveur, created in 1987.

See certified biography in Who’s who ©:

https://imgpublic.artprice.com/img/wp/sites/11/2019/10/biographie_oct2019_WhosWho_thierryEhrmann.pdf

Artmarket is a global player in the Art Market with, among other structures, its Artprice department, world leader in the accumulation, management and exploitation of historical and current art market information in databanks containing over 30 million indices and auction results, covering more than 740,000 artists.

Artprice Images® allows unlimited access to the largest Art Market image bank in the world: no less than 180 million digital images of photographs or engraved reproductions of artworks from 1700 to the present day, commented by our art historians.

Artmarket with its Artprice department accumulates data on a permanent basis from 6300 Auction Houses and produces key Art Market information for the main press and media agencies (7,200 publications). Its 4.5 million ‘members log in’ users have access to ads posted by other members, a network that today represents the leading Global Standardized Marketplace® to buy and sell artworks at a fixed or bid price (auctions regulated by paragraphs 2 and 3 of Article L 321.3 of France’s Commercial Code).

Artmarket with its Artprice department, has been awarded the State label "Innovative Company" by the Public Investment Bank (BPI) (for the second time in November 2018 for a new period of 3 years) which is supporting the company in its project to consolidate its position as a global player in the market art.

Artprice by Artmarket’s 2019 Global Art Market Report published in February 2020 :

https://www.artprice.com/artprice-reports/the-art-market-in-2019

Index of press releases posted by Artmarket with its Artprice department:

http://serveur.serveur.com/press_release/pressreleaseen.htm

Follow all the Art Market news in real time with Artmarket and its Artprice department on Facebook and Twitter:

https://www.facebook.com/artpricedotcom/ (4.9 million followers)

https://twitter.com/artmarketdotcom

https://twitter.com/artpricedotcom

Discover the alchemy and universe of Artmarket and its artprice department http://web.artprice.com/video headquartered at the famous Organe Contemporary Art Museum "The Abode of Chaos" (dixit The New York Times): https://issuu.com/demeureduchaos/docs/demeureduchaos-abodeofchaos-opus-ix-1999-2013

L’Obs – The Museum of the Future: https://youtu.be/29LXBPJrs-o

https://www.facebook.com/la.demeure.du.chaos.theabodeofchaos999

(4.5 million followers)

https://vimeo.com/124643720

Photo – https://mma.prnasia.com/media2/1316267/artmarket_festival_peinture_fraiche.jpg?p=medium600 
Logo – https://mma.prnasia.com/media2/1009603/Art_Market_logo.jpg?p=medium600

 

 

Contact Artmarket.com and its Artprice department – Contact: thierry Ehrmann, [email protected]

Related Links :

https://www.artmarket.com

Continue Reading

News

Ria Money Transfer Partners with Thunes, Expanding Its Global Reach Via Mobile Money and Bank Transfers

gbafNews28

The partnership will significantly increase Ria’s customer base, adding more than 100m mobile account users through Thunes’ existing partners in the mobile payments sector.

SINGAPORE, Oct. 20, 2020 /PRNewswire/ — Ria Money Transfer, a global leader in the money transfer industry and subsidiary of Euronet Worldwide Inc. (NASDAQ: EEFT), and global cross-border payment provider Thunes announced today a strategic partnership to enable customers across the globe to send funds directly to millions of mobile wallet users and bank account holders in key emerging markets.

Now, thanks to this partnership, Ria’s extensive agent network can also send funds directly to mobile wallets, beginning with the addition of more than 100 million mobile money users to the company’s beneficiary customer base. The agreement promotes Ria’s continuous expansion in Asia, Africa, and LATAM through Thunes’ connections to digital wallets and banks. These include strong market players like M-Pesa in East Africa as well as MTN Mobile Money across the continent and other wallets in Tanzania, Uganda, Malawi, and Rwanda with more to come. This agreement follows Ria’s strategy to fast-track its digital services, gaining ground in a rapidly evolving market with a growing demand for mobile money and alternative payment solutions.

In addition to its extensive global network, Thunes provides advanced technological capabilities and a robust platform, enabling Ria to further enhance its digital services by delivering a fast, convenient, and affordable payment experience to its customers.

"At Ria, we are always looking for ways to facilitate access to remittance services. It’s vital for so many around the world who rely on funds from abroad to make ends meet," shared Juan Bianchi, CEO of Euronet’s Money Transfer Segment. "Partnering with businesses like Thunes, who understand the important role we play in the everyday life of our customers, is, without a doubt, the best way to continue expanding our digital product offering and global footprint."

Peter De Caluwe, Thunes CEO, commented: "Partnering with Ria, a global leader in the cross-border money transfer sector is another example of the importance of our interoperable payment network. We look forward to working together to drive greater access to financial services in emerging markets across Asia and Africa."

About Ria Money Transfer

Ria, a subsidiary of Euronet Worldwide, Inc. (NASDAQ: EEFT), is a global leader in the money transfer industry. The company is steadfast in its commitment to its clients and their communities, offering fast, secure, and affordable money transfers through a network of over 435,000 locations across more than 160 countries and online at www.riamoneytransfer.com.

About Thunes

Thunes is a B2B cross-border payments network that enables corporates and financial institutions to move funds and provide financial services in emerging markets. Our global platform connects mobile wallet providers, banks, technology companies and money transfer operators in more than 100 countries and 60 currencies. Thunes is headquartered in Singapore with regional offices in London, Shanghai, and New York.

For more information, visit www.thunes.com

Related Links :

http://www.thunes.com

Continue Reading

News

Planful Welcomes Kimberly Simms as Chief Customer Officer

gbafNews28

With Extensive Industry Experience and Customer Success Program Expertise, Simms Will Be a Significant Asset to Planful and the Companies It Serves

REDWOOD CITY, California, Oct. 20, 2020 /PRNewswire/ — Planful Inc., (formerly Host Analytics), the pioneer of Continuous Planning with its cloud platform for financial planning and analysis (FP&A), today announced that Kimberly Simms has joined the Planful executive team as Chief Customer Officer (CCO). In her new role, Simms will drive customer strategy and oversee the company’s customer teams, focusing on delivering faster time to value, use case expansion, and overall growth.

Simms brings over 20 years of leadership and management experience to her new position at Planful, having served in managerial and consulting roles at Anaplan, IBM, HireVue, Trigo Technologies, and Accenture. Simms was previously Vice President of Customer Success at Anaplan, a global cloud planning company, where she drove customer success across the solution delivery lifecycle. More recently, she served as Senior Vice President of Customer Success at HireVue, the global leader in virtual interviewing and assessments technology.

“We’re thrilled to welcome Kimberly to the Planful team,” said Grant Halloran, Chief Executive Officer, Planful. “Her extensive industry experience and deep customer success expertise makes her a tremendous asset to our team and an incredibly valuable advisor to our customers. Her passion for and commitment to innovation in the customer and delivery space further supports our mission to provide the very best customer experience and support in the business.”

At HireVue, Simms built and led a global customer success organization, achieving significantly improved customer engagement that resulted in best-in-class customer retention levels. At Anaplan, she scaled and developed the west coast customer success team during a period of hypergrowth. At IBM, Simms directed sales and delivery to support the analytics portfolio and served as big data practice lead for the information management lab services group. She began her career in consulting at Accenture after graduating from the University of Kansas.

“I’m delighted to join Planful because of the company’s remarkable focus on customers,” Simms said. “Planful has a unique vision for the industry—Continuous Planning—that, along with enabling technology, allows businesses to achieve leaps in agility despite a very dynamic landscape.” 

Planful’s cloud-based Continuous Planning platform accelerates FP&A processes by seamlessly unifying financial planning, financial close and consolidation, reporting, and visual analytics to help Finance leaders drive faster, and more collaborative, planning and decision-making cycles in all areas of the business.

About Planful

Planful (formerly Host Analytics) is the pioneer of Continuous Planning with its cloud platform for financial planning and analysis (FP&A). Planful delivers on the vision of Continuous Planning by accelerating the end-to-end FP&A process and fostering business-wide participation in agile planning and decision-making. More than 800 customers including, Bose, Boston Red Sox, Del Monte, TGI Friday’s, and 23andMe rely on Planful for financial planning and budgeting, dynamic operational planning, financial consolidations, reporting, and visual analytics. Planful is a private company backed by Vector Capital, a leading global private equity firm specializing in transformational investments in established technology businesses.  Learn more at www.planful.com.

Additional Resources
Hear from Planful customers
Discover Continuous Planning use cases
Join the conversation on social media: LinkedIn, Twitter, or Facebook.

Contact
[email protected]

Logo – https://mma.prnasia.com/media2/1077463/Planful_Logo.jpg?p=medium600  

Related Links :

http://www.planful.com

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News3 mins ago

Fuling Global to Hold Extraordinary General Meeting of Shareholders

WENLING, China, Oct. 20, 2020 /PRNewswire/ — Fuling Global Inc. (Nasdaq:  FORK) ("Fuling Global" or the "Company"), a manufacturer and distributor...

gbafNews28 gbafNews28
News3 mins ago

Zcoin Debuts Lelantus: Next-Generation Privacy Protocol Offers High Practical Anonymity Similar to Cash

Leading privacy coin allows users to test the technology in advance of mainnet launch SINGAPORE, Oct. 20, 2020 /PRNewswire/ —...

gbafNews28 gbafNews28
News3 mins ago

Planful Welcomes Kimberly Simms as Chief Customer Officer

With Extensive Industry Experience and Customer Success Program Expertise, Simms Will Be a Significant Asset to Planful and the Companies...

gbafNews28 gbafNews28
News3 mins ago

Ria Money Transfer Partners with Thunes, Expanding Its Global Reach Via Mobile Money and Bank Transfers

The partnership will significantly increase Ria’s customer base, adding more than 100m mobile account users through Thunes’ existing partners in...

gbafNews28 gbafNews28
News3 mins ago

Artprice by Artmarket.com: Condition of the Street Art market worldwide

PARIS, Oct. 20, 2020 /PRNewswire/ — At its online sale on 28 May 2020, Phillips sold Banksy’s lot Happy Choppers...

gbafNews28 gbafNews28
News6 mins ago

More Consumer Education and Collaboration Needed, Argues New Economist Intelligence Unit Study on the Impact of Covid-19 on Illicit Trade

There will be at least five lasting effects from the pandemic, including rising demand for certain categories of illicit goods...

gbafNews28 gbafNews28
News2 hours ago

Mercury Derivatives Trading Selects Eventus Systems for Trade Surveillance

Global Futures Proprietary Trading Firm Deploys Validus Platform AUSTIN, Texas, Oct. 20, 2020 /PRNewswire/ — Eventus Systems, Inc., a multi-award winning...

gbafNews28 gbafNews28
News2 hours ago

VolitionRx Limited Announces Details for Virtual Capital Markets Day 2020

AUSTIN, Texas, Oct. 20, 2020 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company developing simple, easy...

gbafNews28 gbafNews28
News2 hours ago

Samsung Biologics inks development partnership with Dinona for potential COVID-19 treatment

INCHEON, South Korea, Oct. 20, 2020 /PRNewswire/ — Samsung Biologics (207940.KS) has entered into a partnership agreement with biotech Dinona,...

gbafNews28 gbafNews28
News2 hours ago

CoinLock Announces Collaboration with Idoneus, IDON Token Available on Platform Today

– IDON luxury asset token to begin trading on the platform today. – IDON users can now enjoy more utility—like free hedging...